Company / Cash & Equivalents
OCULAR THERAPEUTIX, INC Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$737.1M
FY2025
5-year range
$164.2M / $737.1M
FY2021-FY2025
Trend
+88.0%
vs FY2024
Sector context
#27 of 207
Health Care
What the data says
OCULAR THERAPEUTIX, INC's cash & equivalents of $737M is higher than 87% of companies in the Health Care sector (FY2025). Cash & Equivalents has increased for 3 consecutive years, from $164M in FY2022 to $737M in FY2025.
Based on SEC 10-K filings.
$737M in FY2025 with a 5-year CAGR of +68.4%. Top quartile in the Health Care sector.
Improved from $196M to $737M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +65.0%
- 5-Year CAGR
- +68.4%
- 10-Year CAGR
- -
Sector benchmark
+10.1% above sector average
Key checks
Key Insights
- OCULAR THERAPEUTIX, INC's cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +68.4%, indicating consistent growth.
- In FY2025, cash & equivalents increased 88.0% year-over-year.
- Ranks #27 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.25 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $737.1M | +88.0% |
| FY2024 | $392.1M | +100.2% |
| FY2023 | $195.8M | +19.3% |
| FY2022 | $164.2M | -28.0% |
| FY2021 | $228.1M | +318.9% |
| FY2020 | $54.4M | +0.7% |
| FY2019 | $54.1M | +0.0% |
| FY2018 | $54.1M | +30.2% |
| FY2017 | $41.5M | +26.1% |
| FY2016 | $32.9M | +88.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026